title: Non-Hodgkin's lymphomas, version 1.2013.
abstract: These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Non-Hodgkin's Lymphomas (NHL) and provide a discussion of the clinical evidence that support the updates. The updates discussed in this article feature recommendations for additional treatment options in patients with chronic lymphocytic leukemia and guidance surrounding the management of hepatitis virus reactivation/infections in high-risk patients with NHL undergoing antitumor therapy.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, USA.
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Zelenetz
authors.forename: William G
authors.initials: WG
authors.lastname: Wierda
authors.forename: Jeremy S
authors.initials: JS
authors.lastname: Abramson
authors.forename: Ranjana H
authors.initials: RH
authors.lastname: Advani
authors.forename: C Babis
authors.initials: CB
authors.lastname: Andreadis
authors.forename: Nancy
authors.initials: N
authors.lastname: Bartlett
authors.forename: Naresh
authors.initials: N
authors.lastname: Bellam
authors.forename: John C
authors.initials: JC
authors.lastname: Byrd
authors.forename: Myron S
authors.initials: MS
authors.lastname: Czuczman
authors.forename: Luis E
authors.initials: LE
authors.lastname: Fayad
authors.forename: Martha J
authors.initials: MJ
authors.lastname: Glenn
authors.forename: Jon P
authors.initials: JP
authors.lastname: Gockerman
authors.forename: Leo I
authors.initials: LI
authors.lastname: Gordon
authors.forename: Nancy Lee
authors.initials: NL
authors.lastname: Harris
authors.forename: Richard T
authors.initials: RT
authors.lastname: Hoppe
authors.forename: Steven M
authors.initials: SM
authors.lastname: Horwitz
authors.forename: Christopher R
authors.initials: CR
authors.lastname: Kelsey
authors.forename: Youn H
authors.initials: YH
authors.lastname: Kim
authors.forename: Susan
authors.initials: S
authors.lastname: Krivacic
authors.forename: Ann S
authors.initials: AS
authors.lastname: LaCasce
authors.forename: Auayporn
authors.initials: A
authors.lastname: Nademanee
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Porcu
authors.forename: Oliver
authors.initials: O
authors.lastname: Press
authors.forename: Barbara
authors.initials: B
authors.lastname: Pro
authors.forename: Nishitha
authors.initials: N
authors.lastname: Reddy
authors.forename: Lubomir
authors.initials: L
authors.lastname: Sokol
authors.forename: Lode
authors.initials: L
authors.lastname: Swinnen
authors.forename: Christina
authors.initials: C
authors.lastname: Tsien
authors.forename: Julie M
authors.initials: JM
authors.lastname: Vose
authors.forename: Joachim
authors.initials: J
authors.lastname: Yahalom
authors.forename: Nadeem
authors.initials: N
authors.lastname: Zafar
authors.forename: Mary A
authors.initials: MA
authors.lastname: Dwyer
authors.forename: Maoko
authors.initials: M
authors.lastname: Naganuma
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006509:Hepatitis B / Q000097:blood / Q000139:chemically induced / Q000276:immunology; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects / Q000276:immunology / Q000502:physiology; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy; D006801:Humans; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000628:therapy / Q000821:virology; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000628:therapy* / Q000821:virology; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D014775:Virus Activation / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D013792:Thalidomide; D000077269:Lenalidomide